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Hepatology, Medicine and Policy (HMAP), a new open-access peer-reviewed journal, is making its debut at a time
when the hepatitis field is seeing great progress but still has far to go. The World Health Organization and many
countries have shown increasing interest in viral hepatitis in recent years, helping to foster a stronger response to
this group of diseases. Meanwhile, alcohol-associated cirrhosis and alcohol-associated liver cancer continue to take
a heavy toll worldwide, as does non-alcoholic fatty liver disease. The lack of a unified strategic response to viral
hepatitis and other liver diseases is the impetus for launching HMAP, which will publish policy, public health and
social science articles alongside clinical science articles. It will encourage submissions in diverse domains such as
disease prevention and management, epidemiology, economics, health behavior, health service delivery, ethics,
human rights, and the role of laws, policies and clinical guidelines in shaping health initiatives. The current
attention to powerful new hepatitis C treatments presents a strategic opportunity to more comprehensively
address the full constellation of biomedical and social issues relating to liver health. HMAP is committed to
publishing research and policy articles that help to drive forward this broader agenda.Who needs a magnifying lens?
Pens? Tote bags? T-shirts? I still remember the lengthy
discussion. It was 2006, and I had been tapped as the
World Health Organization (WHO) European office’s
staff representative for the planning of “World Hepatitis
Awareness Day,” as it was called back then.
The newly formed European Liver Patients Association
(ELPA) was determined to raise the profile of this little-
known event, and had engaged WHO/Europe, the
European Association for the Study of the Liver
(EASL) and other organizations in an ambitious pub-
licity campaign.
We finally decided that a key chain displaying the
World Hepatitis Awareness Day logo would be a suitable
“giveaway” item. And we ordered a bulk supply of a flat
wallet-sized magnifying lens, also marked with the logo.
This additional item was for advocates who wanted to
protest public officials’ lack of attention to hepatitis—the
idea was for them to dramatically brandish their lenses
at the appropriate moment and say that they were
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Commons license, and indicate if changes wehepatitis. Such was the state of hepatitis awareness at
the time.
I would like to say we took the world by storm. But in
truth, we didn’t even take my office by storm, and the
European media were largely indifferent to our efforts.
Despite the lackluster response, I was quite pleased
with one outcome that might be best characterized as
“unintentional stealth advocacy from within.” I had
harbored some doubts about the little magnifying lenses,
but this investment demonstrated its worth when I saw
a WHO regional deputy director using one several
months later. She said that she kept it for reading fine
print!
Ten years on from this somewhat ragtag effort, my
continuing engagement in the global response to liver
diseases has led me to found Hepatology, Medicine and
Policy (HMAP). An open-access peer-reviewed journal,
HMAP is making its debut at the time of the World
Health Assembly’s approval of the first Global Health
Sector Strategy on Viral Hepatitis [1]. The establish-
ment of HMAP compels me to reflect on both how far
we have come, in terms of global efforts to combat
hepatitis and other liver diseases, and how far we still
have to go.istributed under the terms of the Creative Commons Attribution 4.0 International
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On the one hand, the World Health Assembly’s first-
ever viral hepatitis resolution in 2010 [2] spurred WHO
to step up and provide much-needed leadership and
technical guidance. Far more people both within and
outside of public health circles are now aware of the
magnitude of hepatitis epidemics in many countries,
and some governments have taken important steps
toward developing effective responses [3]. The patient-
led World Hepatitis Alliance—with which HMAP is
proudly affiliated—has a thriving constituency com-
prised of 230 member organizations in 81 countries [4],
and is a strong catalyst for policy change and civil soci-
ety involvement globally.
Then there is the incredibly exciting news in the realm
of hepatitis C treatment, with the latest drugs achieving
such high cure rates that some stakeholders think it is
time to set our sights on the worldwide elimination of
this disease [1, 5, 6].
On the other hand, there is still no cure for hepa-
titis B and no vaccine against hepatitis C. Efforts to
reduce illness and death from both diseases are ham-
pered by the fact that many of those carrying both vi-
ruses are unaware of their infection [1]. Furthermore,
the cost of treatment—especially treatment with the
newest hepatitis C drugs—presents a major obstacle
to effective clinical care in many countries.
Hepatitis A annually strikes an estimated 1.4 mil-
lion people [7], and hepatitis E, an estimated 20 mil-
lion people [8], with household and community
poverty often serving as underlying factors in the
transmission of these viruses through contaminated
water. Although the burden of disease from both vi-
ruses is concentrated in developing countries, evi-
dence is emerging to suggest that the zoonatic
transmission of hepatitis E virus in developed
countries—primarily through the consumption of
meat from infected animals such as pigs, as well as
through the transfusion of contaminated blood
products—may be a greater cause of illness than pre-
viously recognized, and there are important un-
answered questions about the epidemiology of
hepatitis E disease [9, 10].… And what of the other glasses?
While hepatitis C treatment developments have been gar-
nering headlines, the general public has remained largely
unaware of other major liver health issues. Alcohol-
associated cirrhosis is thought to account for more than
one-quarter of all deaths from cirrhosis annually, and
alcohol-associated cirrhosis and alcohol-associated liver
cancer together cause an estimated 432,000 deaths
annually [11].Regional variations have long been noted, with
North America and Europe leading other regions, but
the global epidemiology of alcoholic liver disease is
shaped in part by complex economic and social fac-
tors that are in a state of flux. Decreases in the price
of alcohol in some countries, for example, or changes
in gender norms or other social norms can lead to
rapid increases in alcohol consumption, with incidence
of hepatic disease increasing in turn. Developing
effective public health policies to address these dy-
namics requires the cross-disciplinary integration of
state-of-the-art knowledge from hepatologists, epide-
miologists, economists, addiction researchers, and
other diverse experts.
Similarly, as non-alcoholic fatty liver disease (NAFLD)
becomes an increasingly prominent health threat in
many parts of the world, the field of hepatitis is being
called upon to address this issue through not only bio-
medical pathways but also through the translation of
biomedical knowledge into sound evidence-based health
policies. While obesity and diabetes are major risk
factors for NAFLD, much work remains to be done
to understand the mediating role of ethnic origin,
gender and other genetic and social factors [12, 13].
The clinical management of NAFLD is not well
understood either, although the available evidence sug-
gests that simplistic efforts to change the diets and physical
activity levels of people with NAFLD are unlikely to
achieve major reductions in the burden of disease from this
condition [14].Needed: a more unified response
Most troubling from my perspective is the lack of a
unified strategic response to viral hepatitis and other liver
diseases. How can policy-makers, researchers, health ser-
vice providers, non-governmental organizations, patient
groups and affected communities harmonize their efforts
to address such a complex situation? What can these
actors contribute to each other’s work?
Most crucially, how can we collectively ensure that the
best new knowledge about disease prevention and treat-
ment is translated as quickly as possible into national-
and local-level interventions that will avert unnecessary
suffering and death?
The impetus for launching HMAP is the recognition
that no suitable forum exists for rigorously examining
these questions on an ongoing basis. The established
hepatology journals are certainly publishing valuable
biomedical and clinical research findings. But it is
imperative to also focus more squarely on health systems
and the people who make up health systems—as service
providers, decision-makers, patients and members of
affected communities.
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HMAP seeks to publish policy, public health and social
science articles as well as clinical science articles from
researchers who are eager to reach a wide audience. We
want to expand the evidence base by addressing issues
as wide-ranging as disease prevention and management,
epidemiology, economics, health behavior, health service
delivery, ethics, human rights, and the role of laws, pol-
icies and clinical guidelines in shaping health initiatives.
We encourage researchers working in all of these areas
to highlight the policy implications of their findings—as
well as the practical implications for health service pro-
viders and for people living with liver diseases or at high
risk. And we encourage non-researchers to “talk back” via
commentaries, roundtable discussion articles, conference
events and online platforms, including the HMAP blog
(featured in the BioMed Central “On Health” blog) [15].
In these and other ways, we greatly look forward to fos-
tering an ongoing dialogue among the many stakeholders
who are driving progress in the field of hepatology.
HMAP has come into being at an exciting time. The
journal began accepting submissions slightly more than
a year after the World Health Assembly passed its sec-
ond viral hepatitis resolution in 2014, calling on govern-
ments to take more concrete actions to combat these
diseases [16]. In September 2015, the first-ever World
Hepatitis Summit brought together stakeholders from 84
countries—including representatives of patient groups,
national governments, WHO and the pharmaceutical
industry—for an unprecedented series of discussions about
what the global response to viral hepatitis should look like
[3]. And in May 2016, the World Health Assembly is ex-
pected to approve the World Health Organization’s first-
ever global health sector strategy on viral hepatitis [1].
These developments, coupled with the dramatic ad-
vances in hepatitis C treatment, doubtlessly explain why
HMAP has received a considerable number of submissions
and pre-submission inquiries addressing hepatitis C specif-
ically. Of course, I embrace the prospect of continuing
to make progress in this area. At the same time, I
recognize that the current attention to HCV offers a
strategic opportunity to more comprehensively ad-
dress the full constellation of biomedical and social
issues relating to liver health. I am eager to see
HMAP publish research and policy articles that help
to drive forward this broader agenda, and am ex-
tremely grateful to HMAP’s editorial board and asso-
ciate editors for helping to point the way forward.Competing interests
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